08D.F MIRUM PHARMAC. DL-0001

Healthcare Biotechnology Frankfurt Exchange
83.30 EUR
Close of Nov 11, 2026
52.50 110.35
Market cap
EUR 5.44B
P/E
-
P/B
25.24x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 08D.F undervalued?

Graham number

The Graham number of MIRUM PHARMAC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MIRUM PHARMAC. DL-0001 fundamental analysis

No fundamental analysis for MIRUM PHARMAC. DL-0001 yet.

MIRUM PHARMAC. DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MIRUM PHARMAC. DL-0001

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved …

Full company profile